Blood Res.  2014 Jun;49(2):130-137. 10.5045/br.2014.49.2.130.

Long-term hematological response in a patient with 5q- syndrome after suspension of lenalidomide therapy and further improvement with deferasirox therapy

• Niscola P
• Tendas A
• Scaramucci L
• Merola R
• Catalano G
• de Fabritiis P

• KMID: 2172810
• DOI: http://doi.org/10.5045/br.2014.49.2.130

Abstract

No abstract available.

MeSH Terms

Humans

Reference

1. Giagounidis AA, Haase S, Heinsch M, Gohring G, Schlegelberger B, Aul C. Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses. Ann Hematol. 2007; 86:133–137. PMID: 17111142.

2. Breccia M, Cannella L, Latagliata R, et al. Unexpected erythroid and cytogenetic responses after discontinuation of a short course of lenalidomide as a result of severe skin rash in a patient with 5q syndrome. J Clin Oncol. 2011; 29:e402–e403. PMID: 21357784.

3. Cannella L, Latagliata R, Breccia M, et al. Very short-term lenalidomide treatment associated with durable resolution of anemia in a patient with myelodysplastic syndrome with chromosome 5q deletion. Ann Hematol. 2012; 91:309–310. PMID: 21625998.

4. Vigna E, Recchia AG, Cuzzola M, Morabito L, Gentile M, Morabito F. Erythroid but not cytogenetic response in a case with 5q- syndrome: a delayed effect of lenalidomide or a consequence of deferasirox treatment? Leuk Lymphoma. 2014; 55:1408–1409. PMID: 23952245.

5. Oliva EN, Schey C, Hutchings AS. A review of anemia as a cardiovascular risk factor in patients with myelodysplastic syndromes. Am J Blood Res. 2011; 1:160–166. PMID: 22432077.

6. Gattermann N, Finelli C, Della Porta M, et al. Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes. Haematologica. 2012; 97:1364–1371. PMID: 22419577.

7. Molica M, Salaroli A, Alimena G, Breccia M. Haematological improvement as a beneficial effect during deferasirox treatment in transfusion-dependent patients with myelodysplastic syndrome. Blood Transfus. 2014; 12(Suppl 1):s162–s163. PMID: 23736908.

8. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89:2079–2088. PMID: 9058730.

9. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007; 25:3503–3510. PMID: 17687155.

10. Niscola P, Vischini G, Tendas A, et al. Management of hematological malignancies in patients affected by renal failure. Expert Rev Anticancer Ther. 2011; 11:415–432. PMID: 21417855.